Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 9.3 years: an updated integrated safety analysis
| Main Authors: | , , , , , , , , , , |
|---|---|
| Formato: | Conference item |
| Idioma: | English |
| Publicado em: |
Journal of Rheumatology
2022
|
| Resumo: |
|---|